Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV003298138 | SCV003999870 | uncertain significance | Familial thoracic aortic aneurysm and aortic dissection | 2023-04-11 | criteria provided, single submitter | clinical testing | The c.1870-2A>G intronic variant results from an A to G substitution two nucleotides upstream from coding exon 27 in the COL3A1 gene. This variant has been detected in a vascular Ehlers-Danlos syndrome cohort; however, details were limited (Pepin MG et al. Genet Med, 2014 Dec;16:881-8). Alterations that disrupt the canonical splice site are expected to result in aberrant splicing. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site. The resulting transcript is predicted to be in-frame and is not expected to trigger nonsense-mediated mRNA decay; however, direct evidence is unavailable. The exact functional effect of the altered amino acid sequence is unknown. This nucleotide position is highly conserved in available vertebrate species. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| Collagen Diagnostic Laboratory, |
RCV000087662 | SCV000120554 | pathogenic | Ehlers-Danlos syndrome, type 4 | no assertion criteria provided | clinical testing |